MedPath

An observational controlled study on vaginal blood flow and sexual functioning after early stage cervical cancer treatment

Conditions
10029903
cancer of the cervix
cervical cancer
10038588
10046828
Registration Number
NL-OMON42343
Lead Sponsor
eids Universitair Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

Pre-menopausal women who have undergone conventional radical hysterectomy with pelvic lymphadenectomy using the Okabayashi method (RHL-WO) at the AMC for the treatment of early stage cervical cancer (FIGO IA2 * IIA). Women are selected on pre-menopausal status because menopausal status can influence the vaginal bloodflow. Women with a history of cervical cancer can be included if treatment has been completed at least 12 months before. All eligible patients have been treated for FIGO stage IA2-IIA cervical cancer with therapyRHL-WO; have no signs of recurrent or metastatic cervical cancer after 1 year; have not received external beam radiation therapy, intravaginal brachytherapy and/or concomitant chemotherapy; did not have their ovaries removed during surgery; are capable of understanding, reading and writing the Dutch language; are not pregnant; have performance status of WHO 1-2, Karnofsky >60; and are <75 52 years of age. Use of medication and hormonal substitutes is registered.

Exclusion Criteria

Women that receive radiotherapy and/or concomitant chemotherapy; had their ovaries removed during surgery; or are pregnant; are not included.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath